Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2016 Nov 7;4(12):1061–1071. doi: 10.1158/2326-6066.CIR-16-0104

Figure 2. Subsets of established MOC1, but not MOC2, tumors reject following CDN monotherapy.

Figure 2

A, established MOC1 tumors (0.1 cm3 volume average) were treated with intratumoral injection of R,R-CDG (15 µg/injection q 3 days × 3, n = 10 mice/group, left panel). Black arrows indicate R,R-CDG injections. Mice were followed for 100 days and survival analyzed (right panel, log-rank/Mantel Cox test). End-point criteria for survival was tumor diameter of 2 cm. B, mice that rejected MOC1 tumors following treatment (5/10 mice) were challenged with 2 × 106 MOC1 cells 30 days after tumor rejection (left panel). Thirty days after this MOC1 challenge, these same mice were challenged with MOC2 (right panel). C, treatment of established MOC2 tumors with intratumoral R,R-CDG (left panel, n = 10 mice/group) and corresponding survival analysis (right panel). D, photographs of control (top, broken line is palpable tumor) and R,R-CDG treated (bottom) MOC1 tumor-bearing mice, demonstrating hair loss and scabbing. Growth curves shown are representative of one of three independent experiments with similar results.